The prevention of contrast medium-induced acute kidney injury is a major challenge for interventional cardiologists. Several patient and procedure-associated risk factors were identified in previous studies. Only a few contrast medium-induced acute kidney injury prevention strategies exist. Ischemic preconditioning has been shown in the
Despite significant improvement in both surgical and medical management of coronary artery bypass graft patients, many experience significant perioperative morbidity that adversely affects quality of life and length of hospitalization and increases resource use. Angiotensin-converting enzyme inhibitors (ACEIs) have been proven effective in the care of cardiovascular patients with hypertensive heart disease and congestive heart failure; however, effect of ACEI on survival in patients undergoing coronary artery bypass graft surgery is equivocal. Unfortunately, ACEI treatment is usually held up before coronary artery bypass graft, primarily because of historical reports linking it to hemodynamic instability during the perioperative period and a larger need for vasoactive drug use and fluid administration. To address these issues, we designed a prospective, international, multi-institutional study that allowed determination of the impact of the current practice pattern of ACEI use on morbidity and mortality after coronary artery bypass graft surgery. We showed that continuation of ACEI therapy early after surgery or adding ACEI de novo postoperatively can be associated with marked improvement in cardiovascular and renal outcomes. Conversely, a practice of withdrawing ACEI treatment postoperatively is associated with poor in-hospital nonfatal outcomes. The associated improvement in outcomes with ACEI therapy was not surprising, given the well-known benefits of blocking the renin-angiotensin-aldosterone system; however, it is alarming to learn that clinicians chose to acutely discontinue ACEI therapy in nearly 50% of patients after cardiac surgery. The present work confirms that acute withdrawal of ACEI therapy may be particularly harmful in the context of cardiac surgery, and attention to restore ACEI therapy soon after operation should be encouraged. See p 261.
Vitamin D May Not Improve Lipid Levels: A Serial Clinical Laboratory Data Study
Vitamin D deficiency is common. Low levels of serum 25hydroxyvitamin D [25(OH)D], the biomarker of vitamin D status, are associated with cardiovascular risk factors, including dyslipidemia. However, clinical trials have yet to show a role for vitamin D repletion in reducing cardiovascular disease or improving the lipid profile. Prospective trials of vitamin D supplementation are underway but will take years to complete and are extremely expensive. We analyzed the Quest Diagnostics clinical database as an expedient and cost-effective method of investigating the relationship between 25(OH)D levels and blood lipids. This study provided data from a clinically relevant, "real-world" setting to verify the cross-sectional associations between 25(OH)D deficiency and the lipid profile. In the same population, we explored whether changes in 25(OH)D from the deficient range (Ͻ20 ng/mL) to the optimal range (30 -100 ng/mL) were associated with beneficial effects on blood lipids. Our cross-sectional analysis found that higher 25(OH)D levels strongly correlated with a healthier lipid profile: lower total and low-density lipoprotein cholesterol, higher high-density lipoprotein cholesterol, and lower triglycerides. In contrast, our longitudinal analysis found that raising 25(OH)D levels from Ͻ20 to Ն30 ng/mL did not have an effect on low-density lipoprotein cholesterol or triglycerides, whereas total and high-density lipoprotein cholesterol both increased Ͻ1 mg/dL. Thus, it is misleading to conflate the epidemiological association of low 25(OH)D levels and dyslipidemia with a presumed benefit of vitamin D supplementation. Until long-term studies are available, clinicians should be cautious and should not expect that vitamin D supplementation will treat hypercholesterolemia in patients who are vitamin D deficient. See p 270.
Influenza Vaccination and Major Adverse Vascular Events in High-Risk Patients
It remains uncertain whether the influenza vaccine is associated with a reduced risk of vascular events, despite at least 10 observational studies and 3 small randomized controlled trials investigating this association. The existing observational studies were limited by small size, involved only a single influenza season, and/or were at risk of significant bias resulting from study design and the presence of confounding. The 3 randomized controlled trials were small with few event rates, precluding any definitive conclusions. We therefore performed an observational study using data from a large multinational trial of patients at high risk for vascular events involving 31 546 participants from 733 centers in 40 countries. Although initial analyses suggest that influenza vaccination was associated with a reduced risk of major adverse vascular events during influenza seasons when the influenza vaccine matched the circulating virus, detailed sensitivity analyses revealed that evidence of risk of confounding bias remained. A randomized trial is needed to definitively address this question. See p 278.
Nitroglycerin Fails to Lower Blood Pressure in Redox-Dead Cys42Ser PKG1␣ Knock-In Mouse
Nitroglycerin (GTN) remains a treatment for unstable angina and hypertension after Ͼ130 years of clinical use. Despite this, the mechanism of action still is not fully understood. Here, we present evidence that GTN induces the oxidation of protein kinase G (PKG)-1␣ such that it forms an interprotein disulfide bond, directly activating the kinase, which couples to blood vessel dilation. This occurs independent of the classic mode of stimulating PKG, in which nitric oxide stimulates the production of cGMP, which then binds to PKG to activate it. Thus, although GTN is an organic nitrate, its mode of kinase activation at therapeutic concentrations is principally through oxidative activation and not cGMP binding. Prolonged (Ͼ24 hours) treatment with GTN commonly results in the well-recognized "tolerance" phenomenon, in which the vasodilatory and antianginal effects of GTN are lost, thus hampering its clinical use. Our studies show tolerance to nitroglycerin is associated with loss of PKG oxidation. If pharmacological interventions can be identified that maintain GTN-induced PKG oxidation during chronic use, this may potentially counteract the development of tolerance. See p 287.
RenPro (Renal Protection) Trial to be an effective, safe, and economic method for prevention of contrast medium-induced acute kidney injury in high-risk patients. The broad application of this method in daily clinical settings may remarkably influence the cardiovascular outcome in high-risk patients. See p 296.
Coronary Computed Tomographic Angiography and Risk of All-Cause Mortality and Nonfatal Myocardial Infarction in Subjects Without Chest Pain Syndrome From the CONFIRM Registry (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry)
This is the first registry analysis to evaluate the additive contribution of coronary computed tomographic angiography (cCTA)-defined coronary artery disease compared with clinical risk factors and coronary artery calcium score in a large international multicenter cohort of individuals without chest pain syndrome. Although the overall prevalence of obstructive coronary artery disease was generally low, our prognostic models revealed an independent prediction of cCTA-defined coronary artery disease for incident mortality and the composite outcome of all-cause mortality and nonfatal myocardial infarction. However, the ability of these findings to improve risk stratification for the prediction of all-cause mortality beyond information derived from coronary artery calcium score was not observed. cCTA offered minimal statistical improvement in risk prediction and reclassification for a composite end point of death and myocardial infarction. Given the ability of cCTA to identify atherosclerotic plaque components beyond calcified plaque, including fibrous, fibrolipoid, and lipoid plaque, future studies examining these plaque characteristics in asymptomatic individuals undergoing cCTA and coronary artery calcium score may be useful to further investigate the present study findings. At present, however, the application of cCTA for risk assessment of individuals without chest pain syndrome beyond coronary artery calcium score does not appear justified. See p 304.
Myocardial CXCR4 Expression Is Required for Mesenchymal Stem Cell Mediated Repair Following Acute Myocardial Infarction
The growing success for the treatment of acute myocardial infarction has led to an increasing prevalence of chronic heart failure. Multiple stem cell populations are under investigation, and, in general, most demonstrate some modest benefit and the potential to improve outcomes of patients with acute myocardial infarction and chronic heart failure. The majority of data suggest that adult stem cells do not induce regeneration of the cardiac myocytes; rather, studies have demonstrated that adult stem cell therapy induces endogenous stem cell-based myocardial repair. One of the important pathways activated by adult stem cells is the SDF-1:CXCR4 axis. The importance of these finds are highlighted by a recently completed multicenter phase I clinical trial demonstrating the safety and efficacy of the endoventricular delivery of plasmid DNA encoding hSDF-1 in patients with New York Heart Association class III chronic heart failure at 4 and 12 months after treatment (http://www.clinicaltrials. gov, NCT01082094). Although SDF-1 has been shown to be critical in myocardial repair post-MI, the relative importance of cardiac stem cell CXCR4 and CM-CXCR4 expression on mesenchymal stem cell-based myocardial repair remains unanswered. Using our novel model of CM-CXCR4 null mice, we dissected the effects of mesenchymal stem cell SDF-1 expression on end-organ tissue repair and demonstrated a critical role for cardiac progenitor cell and cardiac myocyte CXCR4 expression on mesenchymal stem cell -mediated cardiac repair. These findings are the first to define a specific paracrine factor of critical importance in adult stem cell therapy and will directly affect development of stem cell and paracrine factor strategies for the prevention and treatment of cardiac dysfunction in patients with acute myocardial infarction and chronic heart failure. See p 314.
Nitrite Regulates Hypoxic Vasodilation via Myoglobin-Dependent Nitric Oxide Generation
Emerging evidence implicates that inorganic nitrite provides a source for bioactive nitric oxide (NO ⅐ ). Nitrite is reduced to NO ⅐ under circumstances with decreased O 2 or pH levels along physiological gradients or under pathological conditions. Hypoxic vasodilation is a physiological response to low O 2 tension, and the present data elucidate a pivotal in vivo role for endogenous nitrite in vascular responsiveness. Although exogenous nitrite supplementation has been associated previously with tissue protection in preclinical disease models (eg, myocardial infarction and several other local and general pathological conditions), the underlying mechanisms for the reduction of endogenous nitrite remained incompletely understood. We provide evidence for a crucial role for the endogenous nitrite/ myoglobin pathway in this response. Ablation of vascular myoglobin in myoglobin-deficient mice impaired the reduction of exogenous and endogenous nitrite to NO ⅐ , which subsequently caused an extenuated ex vivo and in vivo vasodilatory response under hypoxia. Enhancing the endogenous nitrite levels via administration of nitrite or other NO ⅐ sources may therefore provide beneficial effects in a wide variety of cardiovascular diseases but also points to a potential role of nitrite in other tissues where myoglobin has been located recently. We speculate that increased myoglobin concentrations, as occur during physical exercise training, may further enhance nitritedependent signaling. These findings both provide insight into physiological mechanisms and point to a tractable therapeutic strategy in which nitrite is used as a site-selective vasodilator to circumvent the potentially deleterious effects observed with unselective substances (eg, organic nitrates). See p 325.
Relationship Between Arterial Partial Oxygen Pressure After Resuscitation From Cardiac Arrest and Mortality in Children
Postresuscitation care is an important component that affects outcome after cardiac arrest. Adult studies have suggested a relationship between exposure to hyperoxia and survival in this setting. We undertook a national retrospective cohort study that involved 1875 patients from all pediatric intensive care units in the United Kingdom and Ireland to investigate the relationship between arterial partial oxygen pressure (PaO 2 ) after resuscitation from cardiac arrest and mortality. We found exposure to supranormal oxygen tension was common, with 33% of patients having PaO 2 Ͼ150 mm Hg on the first blood gas. We demonstrated a significant association between early postarrest hyperoxia and increased mortality after admission to the pediatric intensive care unit. A stronger association was also seen between the degree of hypoxia and mortality. Our data lend support for intervention studies to assess the safety and efficacy of using the lowest inspired oxygen concentration that maintains arterial oxyhemoglobin saturation of 94% to 96% in the postresuscitation period. See p 335.
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial demonstrated that dabigatran is well-tolerated and that, compared with warfarin, dabigatran 150 mg BID is more effective at preventing stroke and systemic embolism, whereas dabigatran 110 mg BID is associated with a lower risk of major bleeding. However, because dabigatran does not yet have a specific antidote, and its anticoagulant effect is currently difficult to precisely measure, there is concern that dabigatran may increase the risk of bleeding in patients undergoing invasive procedures, particularly if performed on an emergency basis. The RE-LY trial highlights the importance of this scenario, because 25% of patients underwent at least 1 surgery or invasive procedure within 2 years. This analysis of periprocedural outcomes from RE-LY includes data on Ͼ7500 surgeries and procedures, making it the largest evaluation of any anticoagulant strategy in the periprocedural setting. The open-label design of RE-LY allowed a real-world evaluation of the periprocedural management or anticoagulation and demonstrated that dabigatran-treated patients were 4 times more likely to have their procedure completed within 48 hours of the discontinuation of anticoagulation than patients treated with warfarin. Overall, there was no detectable difference in the rate of minor, major, or fatal bleeding between patients treated with warfarin in comparison with either dose of dabigatran, nor was there any difference in the risk of thromboembolic events. In comparison with patients receiving warfarin, the rates of major bleeding with both doses of dabigatran were also similar in the subgroups of patients having major surgery and those having surgery on an emergency basis. See p 343.
Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials
This study shows that the change in 6-minute walk distance (6MWD) satisfies the statistical criteria as a mediator between drug therapy and clinical outcomes in randomized clinical trials. Thresholds in 6MWD change were identified such that if future drugs produced such changes, it could be inferred that these drugs would produce clinical effects as well. Higher thresholds in 6MWD may need to be used when testing new agents in the presence of background pulmonary arterial hypertension therapies; however, our results indicate that 6MWD is likely not adequate for use as a surrogate end point in pulmonary arterial hypertension clinical trials, because only modest proportions of the effects of drugs on true clinical outcomes are explained by changes in 6MWD. Further research is needed to identify more robust surrogate end points or combinations. See p 349.
